By Sam Kovach-Orr, Sahar Ayinehsazian
May 16, 2023
Delaware recently became the 22nd state to legalize cannabis with the passage of House Bill 1 and House Bill 2. Read this Insights article for key provisions of the laws, including licensing details and program rollout timeline.
By Michelle Bodian, Elliot Choi
May 12, 2023
New York City has seen a proliferation of illicit and unregulated cannabis stores since the Marihuana Regulation & Taxation Act was signed into law on March 31, 2021. To date, enforcement efforts have been limited; however, that could all change with the passage of the Governor’s 2024 budget. Read this article to learn key aspects of the budget provisions concerning the illicit cannabis market.
By Michelle Bodian, Elliot Choi, Brandon Kurtzman, Charles Alovisetti
May 11, 2023
On May 11, 2023, New York’s Cannabis Control Board voted to approve the revised adult-use cannabis regulations. The Office of Cannabis Management (OCM) has indicated adult-use cannabis applications will open up in the fall, meaning these revised regulations will function as our roadmap. This article outlines key changes in the revised regulations.
By Michelle Bodian, Shawn Hauser, Shane Pennington
May 11, 2023
At a DEA supply chain conference last week, Terrance Boos, Section Chief, Drug and Chemical Evaluation Section, stated that the DEA will be releasing a rule to reschedule certain hemp-derived cannabinoids.
May 11, 2023
With ketamine being the only approved psychedelic drug for medical use, ketamine clinics offer a unique opportunity for investors and entrepreneurs looking to enter the expanding market of innovative mental health therapies. In this article, we will explore the reasons behind the growing demand for ketamine clinics and the unique regulatory considerations involved in transactions involving these businesses.
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.